Lars Henrik Jensen
Vejle Sygehus(DK)
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Genetic factors in colorectal cancer, Cancer Genomics and Diagnostics, Cholangiocarcinoma and Gallbladder Cancer Studies, Pancreatic and Hepatic Oncology Research
Most-Cited Works
- → Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer(2020)2,821 cited
- → Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study(2022)842 cited
- → High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study(2015)542 cited
- → Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial(2015)227 cited
- → Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial(2021)213 cited
- → Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study.(2020)196 cited
- → Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer(2024)170 cited
- → Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial(2025)130 cited
- → Prognostic factors for progression-free and overall survival in advanced biliary tract cancer(2015)112 cited
- → Neoadjuvant chemotherapy in locally advanced colon cancer.A phase II trial(2015)112 cited